SAMBA II is a real game changer in infectious disease management. It is fully automated, performing sample preparation, extraction, amplification and detection: a true sample in – result out system. With SAMBA II, high-tech diagnostic and treatment monitoring assays become easy to perform and require minimal training. While-you-wait results enable test and treat facilities, enhancing the way diseases are managed.
The SAMBA II system is comprised of the assay module, where the test is performed, and the tablet module, which controls the assay module and displays the test results. Each tablet module can control up to four assay modules, allowing flexibility and scalability at sites using SAMBA II.
|Operating Conditions||Temperature range 10-38°C; relative humidity of up to 80%|
For further information please contact us.
SAMBA II is a connected platform. The tablet module controls the assay module and receives all results via Bluetooth. The tablet module can send results to the Bluetooth printer, or via SMS, mobile Internet or Wi-Fi to a backup tablet or a tablet in a remote clinic who send their samples to be tested with SAMBA II. The tablet module can also send test results in a standard format to a laboratory information system (LIS), to a Ministry of Health service or to the SAMBA dashboard. Test results can also be downloaded directly from the tablet via USB. With SAMBA II, test results can be sent to those that need them.
Safe and easy to use – the uniquely shaped ready-to use cartridges are easy to load and include all consumables. The visual results are automatically analysed by the integrated camera to ensure consistent and accurate interpretation, with results presented and stored on the connected tablet.
I think SAMBA II has put that technology on our table!
Dr. G. Gwinji, Former Permanent Secretary, Ministry of Health and Child Care of Zimbabwe
SAMBA II delivers innovative assays in an easy-to-use and accessible platform for the diagnosis and treatment monitoring of infectious disease at the point of care. We are committed to expanding our test menu to cover more infectious agents, with hepatitis B and C tests expected to be released in 2020 and other tests including influenza A and B, and other sexually-transmitted infections in development.
In vitro nucleic acid amplification test for the semi-quantitative detection of HIV-1 in human whole blood.
In vitro nucleic acid amplification test for the qualitative detection of HCV viral RNA in human whole blood.
In vitro nucleic acid amplification test for the qualitative detection of SARs-CoV-2 in human nasal and throat swabs.
Nucleic-acid based amplification test for the qualitative detection of nucleic acids from SARS-CoV-2, Influenza A and/or Influenza B in human respiratory specimens (combined nasal and throat, nasal or nasopharyngeal swabs).
Nucleic-acid based amplification test for the qualitative detection of nucleic acids from SARS-CoV-2 and/or Respiratory Syncytial Virus (RSV) in human respiratory specimens (combined nasal and throat/nasal/nasopharyngeal swabs).